February 10, 2020 07:26 AM ESTUpdated July 6, 11:34 AM
Bioregnum
Special
Opinion

The top 10 bio­phar­ma pipeline blowups, set­backs and sna­fus for H2 2019

Every 6 months, as long­time fol­low­ers will know, I like to list the top 10 dis­as­ters in clin­i­cal R&D. And it seems like every new round-ups the ante a lit­tle more on just what qual­i­fies for a top bloop­er of the year.

H2 2019 is cer­tain­ly a stand­out, with a Big Phar­ma da­ta scan­dal, a cou­ple of block­buster M&A busts and a whole run of Alzheimer’s set­backs to con­tem­plate as we watch the Bio­gen saga play out. Not on­ly does the Alzheimer’s field con­tin­ue to crater, but we watched an­tibi­otics come apart in the last 6 months of 2019.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times